查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1924731

Pomalidomide胶囊市场按规格、适应症、治疗线和通路- 全球预测 2026-2032

Pomalidomide Capsules Market by Strength, Indication, Treatment Line, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，Pomalidomide胶囊市场价值将达到 10.6 亿美元，到 2026 年将成长至 11.5 亿美元，到 2032 年将达到 20.1 亿美元，年复合成长率为 9.55%。

关键市场统计数据
基准年 2025 10.6亿美元
预计年份：2026年 11.5亿美元
预测年份 2032 20.1亿美元
复合年增长率 (%) 9.55%

针对医疗机构中Pomalidomide胶囊的临床定位、相关人员影响和营运考虑进行策略概述

Pomalidomide胶囊已成为血液肿瘤治疗领域的重要选择，尤其适用于治疗方案复杂、需要安全性良好且疗效确切的口服药物的情况。本概要总结了Pomalidomide的临床应用依据、其与其他治疗药物的定位，以及商业性和临床相关人员在将其纳入治疗流程时应考虑的策略因素。下文将基于真实世界的处方模式进行实证分析，重点阐述其对药学委员会、医院药房主任和专科药品经销商的实际意义。

揭示临床实践、监管应对措施和获取模式的变革性变化，以重塑泊Pomalidomide胶囊的处方和给药方式

在临床创新、监管调整和治疗模式演变的推动下，Pomalidomide胶囊的治疗和商业性格局正在经历变革性变化。近期临床试验结果和真实世界证据正在加深我们对Pomalidomide潜在价值的理解，促使临床医生重新评估治疗顺序策略，并探索能够在延长疗效的同时控制毒性的新型组合方案。

检验2025年美国关税调整对口服抗癌产品的供应、采购和取得的累积营运和商业影响

美国于2025年实施的新关税对透过全球分销网路运输的药品供应链和商业性活动产生了显着影响。对于一家口服抗癌药物的生产商和经销商，关税带来的成本压力迫使其重新评估筹资策略、货运路线以及与第三方物流供应商的合约条款。因此，采购团队优先考虑供应链的韧性和供应商多元化，以确保供应的连续性免受关税波动的影响。

详细的细分资讯揭示了剂量、适应症、通路和治疗方案如何相互作用，从而影响临床应用和商业策略。

市场区隔分析揭示了一些微妙的模式，相关人员在对Pomalidomide胶囊进行治疗和商业性定位时应考虑这些模式。按剂型划分，市场分析涵盖 1 毫克、2 毫克、3 毫克和 4 毫克四种规格，这些剂量方案会影响处方柔软性、毒性管理和依从性。临床医师倾向于选择较低剂量来调整合併症患者的治疗方案，而较高剂量则在既定的剂量方案中发挥重要作用，以实现对疾病的有效控制。

全面的区域情报突显了美洲、欧洲、中东和非洲以及亚太地区如何对药品取得、报销和分销产生不同的影响。

区域趋势对Pomalidomide胶囊在不同医疗保健系统中的引入、报销和分发方式有显着影响。在美洲，集中式支付系统和私人保险并存，导致获取途径多样化，这就要求生产商制定全国性的合约策略和社区患者援助计划。法规环境强调核准后证据的收集，而临床实践模式则倾向于由多学科肿瘤委员会来制定治疗顺序决策。

推动Pomalidomide领域成功商业化、证据产生和生命週期规划的关键公司层面趋势和策略性倡议

Pomalidomide市场的企业活动反映了临床投资、生命週期管理和商业性伙伴关係的整合。专注于口服肿瘤药物的主要企业通常会将强大的临床开发项目与有针对性的真实世界证据产生相结合，以支持适应症扩展和与支付方的谈判。与专科经销商和药品福利管理机构的策略联盟能够建构整合的患者支持生态系统，从而解决用药依从性、毒性管理和报销协助等问题。

为实现持续推广，经营团队可采取切实可行的策略要务，加强证据支持、增强供应韧性、倡导病患权益、促进支付方参与。

产业领导者应采取一系列切实有效、影响深远的措施，以确保Pomalidomide胶囊在临床上的应用，维持药物可近性，并优化供应稳定性。应优先考虑整合证据策略，将随机试验结果与真实世界数据结合，以证明其在预期适应症和治疗方案中的疗效。这种方法将增强向支付方论证其价值，并透过将数据转化为可操作的治疗指南来支持临床实践。

我们采用透明的混合方法调查方法，结合文献综合、相关人员访谈和情境分析，以确保研究结果的稳健性和可重复性。

本报告的调查方法结合了对同行评审文献、监管申报文件和临床试验註册数据的系统性回顾，以及对临床、支付方和分销领域关键相关人员的重点一手调查。资料收集着重于近期临床试验结果、上市后警戒调查结果和监管标籤变更记录。一手访谈补充了二手研究结果，捕捉了医院药剂师、专科药房经理和肿瘤药物商业负责人的运作细节。

简明扼要地总结了临床、运作和可近性方面的必要因素，这些因素将决定泊Pomalidomide胶囊的持续应用和患者可近性。

Pomalidomide胶囊在血液肿瘤学领域占据着独特且不断发展的地位，这得益于临床证据支持其用于某些晚期治疗适应症，以及强调患者权益和供应链完整性的商业性实践。更广泛的格局反映了证据生成、监管行动和支付方决策之间日益加速的相互作用，这些因素共同塑造着製造商和医疗服务提供者的准入途径和营运重点。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章Pomalidomide胶囊市场（依规格）

  • 1mg
  • 2mg
  • 3mg
  • 4mg

第九章Pomalidomide胶囊市场依适应症划分

  • 多发性骨髓瘤
  • 骨髓发育不良症候群

第十章Pomalidomide胶囊市场，依治疗线划分

  • 二级治疗
  • 三级治疗

第十一章Pomalidomide胶囊市场（依通路划分）

  • 在线的
  • 离线

第十二章Pomalidomide胶囊市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章Pomalidomide胶囊市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国泊Pomalidomide胶囊市场概况

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国Pomalidomide胶囊市场

第十六章：中国Pomalidomide胶囊市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Admac Pharma Limited
  • Alkem Laboratories Limited
  • Amerigen Life Sciences LLP
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Celgene Corporation
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • EBIO Global Trade LLP
  • Encore Healthcare Private Limited
  • Glenmark Pharmaceuticals Limited
  • Hetero Healthcare Limited
  • Intas Pharmaceuticals Limited
  • Natco Pharma Limited
  • Pharmalink Laboratories Private Limited
  • Sandoz AG
  • Shree Lokanath Pharmaceuticals Private Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-7A380DA7C45F

The Pomalidomide Capsules Market was valued at USD 1.06 billion in 2025 and is projected to grow to USD 1.15 billion in 2026, with a CAGR of 9.55%, reaching USD 2.01 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.06 billion
Estimated Year [2026] USD 1.15 billion
Forecast Year [2032] USD 2.01 billion
CAGR (%) 9.55%

A strategic introduction synthesizing clinical positioning, stakeholder implications, and operational considerations for pomalidomide capsules across healthcare settings

Pomalidomide capsules have emerged as a critical therapeutic agent in hematology-oncology, especially where complex treatment sequences demand oral agents with manageable safety profiles and proven efficacy. This executive overview synthesizes the clinical rationale behind pomalidomide use, its positioning relative to other therapeutic classes, and the strategic levers that commercial and clinical stakeholders must consider when integrating this agent into treatment algorithms. The content that follows emphasizes actionable implications for formulary committees, hospital pharmacy directors, and specialty distributors while maintaining an evidence-informed lens on real-world practice patterns.

Clinical adoption of pomalidomide reflects a convergence of improved patient tolerability, oral administration convenience, and evolving evidence in later-line indications. Translational insights from recent studies underscore how dosing flexibility and combination regimens influence both care delivery and prescriber preference. Consequently, decision-makers must weigh clinical merits alongside supply chain considerations, reimbursement dynamics, and patient access pathways. By framing pomalidomide capsules within these intersecting dimensions, the introduction sets the stage for deeper analysis of landscape shifts, tariff impacts, segmentation nuances, regional differentials, and corporate strategy implications presented in subsequent sections.

Unpacking the transformative shifts in clinical practice, regulatory action, and access models reshaping how pomalidomide capsules are prescribed and delivered

The therapeutic and commercial landscape for pomalidomide capsules is undergoing transformative shifts driven by clinical innovation, regulatory adaptations, and evolving treatment paradigms. Recent clinical trial results and real-world evidence have expanded the understanding of where pomalidomide delivers the most value, prompting clinicians to reassess sequencing strategies and to consider novel combination regimens that can extend efficacy while managing toxicity.

Concurrently, regulatory pathways and label updates are shortening the time between clinical insight and formulary impact, which places a premium on agile medical affairs and evidence generation teams. Observational data and post-marketing surveillance have sharpened the safety profile, reinforcing the importance of structured monitoring protocols in hospital pharmacy settings. Payers are responding to these clinical developments by refining coverage criteria and utilization management approaches, which in turn affects how manufacturers and distributors engage with stakeholders.

Market access and commercialization are also being reshaped by patient-centric models that prioritize adherence and continuity of care; oral oncology agents like pomalidomide require integrated support programs, including adherence counseling and side-effect mitigation services. Finally, cross-sector collaboration between clinical investigators, regulatory affairs, and supply chain partners is becoming essential to manage product availability and to optimize treatment pathways across diverse practice environments.

Examining the cumulative operational and commercial consequences of United States tariff adjustments in 2025 on supply, procurement, and access for oral oncology products

The imposition of new tariff measures in the United States in 2025 introduced discrete supply chain and commercial implications for pharmaceutical products transported through global distribution networks. For manufacturers and distributors of oral oncology agents, these tariff-driven cost pressures necessitated a reevaluation of sourcing strategies, freight routing, and contractual terms with third-party logistics providers. As a result, procurement teams prioritized supply chain resilience and supplier diversification to insulate supply continuity from tariff-induced volatility.

Clinicians and hospital pharmacies experienced indirect effects as procurement cycles lengthened and tender negotiations incorporated incremental duties and customs complexities. Contract administrators renegotiated clauses related to landed cost and delivery timelines, and some organizations expanded local warehousing capacity to mitigate transit disruptions. Parallel to these operational adjustments, payer contracting teams revisited formulary placement strategies to reflect changes in acquisition cost structures and to negotiate risk-sharing agreements that could offset temporary price pressure.

Pharmaceutical companies responded by accelerating nearshoring and dual-sourcing initiatives where feasible, and by engaging in proactive regulatory and customs planning to secure preferential treatment where legitimate tariff exemptions applied. The aggregate of these responses strengthened supply chain agility and highlighted the importance of scenario planning in commercial operations, while reinforcing the need for transparent dialogue among manufacturers, distributors, and payers to preserve patient access during periods of trade-induced cost fluctuation.

Detailed segmentation intelligence revealing how dosing, indication, distribution channel, and line of therapy interact to shape clinical use and commercial strategy

Segmentation insights reveal nuanced patterns that stakeholders must consider when positioning pomalidomide capsules across therapeutic and commercial dimensions. Based on Strength, market is studied across 1 Mg, 2 Mg, 3 Mg, and 4 Mg, and these dose formulations inform prescribing flexibility, toxicity management, and adherence considerations; clinicians often select lower strengths to titrate therapy in patients with comorbidities, while higher strengths play a role in established dosing regimens for robust disease control.

Based on Indication, market is studied across Multiple Myeloma and Myelodysplastic Syndrome, and the distinct clinical pathways for these indications create differentiated demand profiles. In Multiple Myeloma, pomalidomide has a central role in later-line combination strategies, influencing patient support needs and specialty pharmacy engagement. In Myelodysplastic Syndrome, the therapeutic rationale requires careful hematologic monitoring and collaboration between oncology and hematology services to optimize outcomes.

Based on Distribution Channel, market is studied across Hospital Pharmacy and Retail Pharmacy, and distribution choice affects inventory governance, reimbursement interactions, and patient counseling practices. Hospital pharmacies manage inpatient and outpatient oncologic care continuity, whereas retail specialty pharmacies often provide enhanced medication access programs and adherence services. Based on Treatment Line, market is studied across Second Line and Third Or Later Line, and treatment-line segmentation drives clinical expectation setting, payer negotiation dynamics, and the design of promotional and educational initiatives targeted at prescribers and multidisciplinary care teams.

Taken together, these segmentation lenses offer a multidimensional view of how formulation, indication, distribution, and treatment sequencing intersect to shape utilization patterns, clinical workflows, and commercial tactics. Understanding these intersections allows stakeholders to craft differentiated value propositions for each clinical and distribution scenario.

Comprehensive regional intelligence highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific differentially influence access, reimbursement, and distribution

Regional dynamics exert a strong influence on how pomalidomide capsules are adopted, reimbursed, and distributed across diverse healthcare systems. In the Americas, centralized payer systems and private insurance coexist, creating heterogeneous access pathways that require manufacturers to deploy both national contracting strategies and localized patient support programs. The regulatory environment emphasizes post-authorization evidence collection, and clinical practice patterns favor multidisciplinary tumor boards that shape therapeutic sequencing decisions.

Europe, Middle East & Africa present a mosaic of regulatory frameworks and reimbursement philosophies where national health technology assessment outcomes and local budgetary constraints can significantly affect uptake. Stakeholders operating in this region often align clinical evidence generation with country-specific value dossiers and invest in health economics and outcomes research to demonstrate real-world benefit across payer segments. Supply chain considerations vary widely, with some markets requiring dedicated cold chain or controlled distribution infrastructure and others necessitating targeted educational outreach to hematology specialists.

Asia-Pacific encompasses both advanced markets with established specialty pharmacy networks and emerging markets with evolving oncology care capacity. Regulatory timelines and importation policies differ, prompting tailored launch sequencing and phased market entry strategies. In many Asia-Pacific markets, co-pay structures and out-of-pocket dynamics shape patient access, making patient assistance programs and locally adapted adherence support essential. Across all regions, collaborative engagement with clinicians, payers, and pharmacy stakeholders remains critical to driving sustainable access and ensuring that clinical benefit translates into measurable patient outcomes.

Key company-level dynamics and strategic behavior that drive successful commercialization, evidence generation, and lifecycle planning in the pomalidomide sector

Corporate behavior in the pomalidomide landscape demonstrates a blend of clinical investment, lifecycle management, and commercial partnerships. Leading companies focused on oral oncology agents typically combine robust clinical development programs with targeted real-world evidence generation to support label expansion and payer discussions. Strategic alliances with specialty distributors and pharmacy benefit managers enable integrated patient support ecosystems that address adherence, toxicity management, and reimbursement navigation.

Operationally, vendors emphasize manufacturing quality controls and supply redundancy to minimize disruptions, while commercial teams prioritize tailored messaging to hematology-oncology centers and integrated delivery networks. R&D organizations invest in combination trials that pair pomalidomide with novel agents, seeking to enhance efficacy or reduce adverse event profiles. Simultaneously, market entrants and incumbents monitor patent landscapes and regulatory exclusivity timelines to inform lifecycle strategies, including potential formulation developments or differentiated support services.

Given the competitive and regulatory complexity of oncology therapeutics, companies that succeed tend to adopt cross-functional approaches that align clinical evidence, market access planning, and localized commercialization tactics. Executives must also balance short-term access objectives with long-term innovation planning to sustain therapeutic relevance and to respond to evolving standards of care.

Actionable strategic imperatives for executives to strengthen evidence, supply resilience, patient support, and payer engagement for sustained adoption

Industry leaders should adopt a set of pragmatic, high-impact actions to secure clinical adoption, preserve access, and optimize supply resilience for pomalidomide capsules. Prioritize integrated evidence strategies that marry randomized trial outcomes with real-world data to demonstrate comparative effectiveness across the intended indications and treatment lines. This approach strengthens value narratives for payers and supports clinical engagement by translating data into practical treatment guidance.

Enhance supply chain robustness by diversifying sourcing, implementing dual-sourcing where feasible, and increasing visibility across logistics pathways to anticipate and mitigate tariff or customs disruptions. Simultaneously, invest in scalable patient support programs that address adherence, toxicity management, and financial assistance, ensuring that oral delivery translates into sustained therapeutic continuity. Align commercial messaging to reflect segmentation realities-dose-specific clinical guidance, indication-based educational materials, and distribution-focused operational protocols-so that stakeholders receive targeted, pragmatic resources.

Finally, cultivate payer partnerships through outcomes-based contracting and evidence-sharing agreements that align reimbursement with real-world performance. Engage early with regional health authorities to understand reimbursement criteria and to adapt dossiers or health economic models to local expectations. By executing these prioritized actions, organizations can accelerate adoption, protect patient access, and build durable competitive differentiation in an evolving therapeutic landscape.

Transparent mixed-methods research approach combining literature synthesis, stakeholder interviews, and scenario analysis to ensure robust and reproducible insights

The research methodology underpinning this report combines a systematic review of peer-reviewed literature, regulatory filings, and clinical trial registries with targeted primary research among key stakeholders in clinical, payer, and distribution roles. Data collection emphasized contemporary clinical trial outcomes, post-marketing safety surveillance findings, and documented changes in regulatory labeling. Primary interviews supplemented secondary insights, capturing operational nuances from hospital pharmacists, specialty pharmacy managers, and commercial leaders engaged in oncology therapeutics.

Analytical methods included qualitative synthesis of therapeutic positioning, crosswalks between treatment-line protocols and distribution pathways, and scenario-based assessment of supply chain exposures to tariff dynamics. Consistency checks and triangulation were applied to reconcile variations across data sources and to validate interpretative conclusions. Where regional heterogeneity emerged, the methodology incorporated contextual adjustments to reflect local regulatory frameworks, reimbursement processes, and care delivery models.

The approach prioritized transparency and reproducibility, documenting source provenance for clinical and operational assertions and applying conservative interpretation where evidence was limited. This mixed-methods framework ensured that conclusions are grounded in both robust secondary evidence and the practical experience of frontline stakeholders.

Concise conclusion synthesizing clinical, operational, and access imperatives that determine sustainable adoption and patient access for pomalidomide capsules

Pomalidomide capsules occupy a distinct and evolving position within hematology-oncology, supported by clinical evidence that supports their use in specific later-line indications and by commercial practices that emphasize patient support and supply chain integrity. The broader landscape reflects accelerating interaction between evidence generation, regulatory action, and payer decision-making, which together shape access trajectories and operational priorities for manufacturers and healthcare providers.

Looking across segmentation and regional dimensions, successful deployment of pomalidomide requires nuanced alignment of dosing options with clinical workflows, distribution strategies tailored to hospital and retail channels, and localized market access approaches that resonate with national reimbursement frameworks. Operational resilience, particularly in the face of tariff-driven disruptions and shifting logistics dynamics, remains a critical determinant of uninterrupted patient access.

In sum, stakeholders who integrate rigorous evidence strategies with proactive supply and access planning will be best positioned to translate clinical benefit into routine, sustainable care delivery. These conclusions underscore the importance of cross-functional coordination and targeted investment to navigate the clinical and commercial complexities inherent to oral oncology therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pomalidomide Capsules Market, by Strength

  • 8.1. 1 Mg
  • 8.2. 2 Mg
  • 8.3. 3 Mg
  • 8.4. 4 Mg

9. Pomalidomide Capsules Market, by Indication

  • 9.1. Multiple Myeloma
  • 9.2. Myelodysplastic Syndrome

10. Pomalidomide Capsules Market, by Treatment Line

  • 10.1. Second Line
  • 10.2. Third Or Later Line

11. Pomalidomide Capsules Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Pomalidomide Capsules Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pomalidomide Capsules Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pomalidomide Capsules Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Pomalidomide Capsules Market

16. China Pomalidomide Capsules Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Admac Pharma Limited
  • 17.6. Alkem Laboratories Limited
  • 17.7. Amerigen Life Sciences LLP
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Cadila Pharmaceuticals Limited
  • 17.10. Celgene Corporation
  • 17.11. Cipla Limited
  • 17.12. Dr. Reddy's Laboratories Limited
  • 17.13. EBIO Global Trade LLP
  • 17.14. Encore Healthcare Private Limited
  • 17.15. Glenmark Pharmaceuticals Limited
  • 17.16. Hetero Healthcare Limited
  • 17.17. Intas Pharmaceuticals Limited
  • 17.18. Natco Pharma Limited
  • 17.19. Pharmalink Laboratories Private Limited
  • 17.20. Sandoz AG
  • 17.21. Shree Lokanath Pharmaceuticals Private Limited
  • 17.22. Sun Pharmaceutical Industries Limited
  • 17.23. Teva Pharmaceutical Industries Ltd.
  • 17.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POMALIDOMIDE CAPSULES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POMALIDOMIDE CAPSULES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 1 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 1 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 1 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 2 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 2 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 2 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 3 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 3 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 3 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 4 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 4 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY 4 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY THIRD OR LATER LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY THIRD OR LATER LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY THIRD OR LATER LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS POMALIDOMIDE CAPSULES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GCC POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 85. GCC POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. GCC POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 87. GCC POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. G7 POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 100. G7 POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. G7 POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 102. G7 POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NATO POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 105. NATO POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NATO POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 107. NATO POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL POMALIDOMIDE CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA POMALIDOMIDE CAPSULES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)